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Background. Parasite clearance time after artemisinin-based combination therapy (ACT) may be increasing in
Asian and African settings. The association between parasite clearance following ACT and transmissibility is cur-
rently unknown.
Methods. We determined parasite clearance dynamics by duplex quantitative polymerase chain reaction
(qPCR) in samples collected in the ﬁrst 3 days after treatment of uncomplicated malaria with ACT. Gametocyte car-
riage was determined by Pfs25 quantitative nucleic acid sequence–based ampliﬁcation assays; infectiousness to mos-
quitoes by membrane-feeding assays on day 7 after treatment.
Results. Residual parasitemia was detected by qPCR in 31.8% (95% conﬁdence interval [CI], 24.6–39.8) of the
children on day 3 after initiation of treatment. Residual parasitemia was associated with a 2-fold longer duration of
gametocyte carriage (P = .0007), a higher likelihood of infecting mosquitoes (relative risk, 1.95; 95% CI, 1.17–3.24;
P = .015), and a higher parasite burden in mosquitoes (incidence rate ratio, 2.92; 95% CI, 1.61–5.31; P < .001). Chil-
dren with residual parasitemia were also signiﬁcantly more likely to experience microscopically detectable parasite-
mia during follow-up (relative risk, 11.25; 95% CI, 4.08–31.01; P < .001).
Conclusions. Residual submicroscopic parasitemia is common after ACT and is associated with a higher trans-
mission potential. Residual parasitemia may also have consequences for individual patients because of its higher
risk of recurrent parasitemia.
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Reduced susceptibility of Plasmodium falciparum to
artesunate monotherapy has been reported in western
Cambodia [1, 2] and was recently shown to have
emerged in or spread westward to the Thailand–
Myanmar border [3]. The time to clearance of parasites
after meﬂoquine-artesunate combination therapy is
also becoming longer along the Thailand–Cambodia
border [4], and treatment failure rates of meﬂoquine-
artesunate or artemether-lumefantrine (AL) often
exceed 10% [5–8]. Reduced susceptibility to artemisi-
nin-combination therapy (ACT) may also affect the
Received 3 June 2013; accepted 7 August 2013; electronically published 14
August 2013.
Correspondence: Teun Bousema, PhD, London School of Hygiene and Tropical
Medicine, London, United Kingdom (teun.bousema@lshtm.ac.uk).
The Journal of Infectious Diseases 2013;208:2017–2024
© The Author 2013. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. This is an Open Access article distributed under
the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence
(http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial
reproduction and distribution of the work, in any medium, provided the original
work is not altered or transformed in any way, and that the work properly cited. For
commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/infdis/jit431
Parasite Clearance After ACT and Malaria Transmission • JID 2013:208 (15 December) • 2017
African continent, where the majority of countries have
adopted ACT as ﬁrst-line antimalarial treatment.
In the ﬁrst such report from Africa, a measurable increase in par-
asite clearance time after AL and dihydroartemisinin-piperaquine
(DP) was reported in coastal Kenya during 2005–2009 [9]. Par-
asite clearance time is inﬂuenced by parasite drug susceptibility,
parasite density before initiation of treatment, and interindivid-
ual differences in antimalarial pharmacokinetics and immuni-
ty [10, 11]. With the decline in transmission intensity in various
regions in Africa [12, 13] and consequent changes in the rate at
which immunity is acquired, time trends in parasite clearance
times are difﬁcult to interpret [9]. Detailed monitoring of para-
site clearance dynamics after ACT is needed to determine
whether parasite responsiveness to ACT is changing. Clearance
dynamics in vivo can be analyzed as the parasite half-life if
blood samples are obtained more than once per day after treat-
ment [2, 11] or as the simple presence or absence of parasites at
a single time point after initiation of treatment [14]. A simple
duplex quantitative polymerase chain reaction (qPCR) method
has been proposed for the analysis of sequentially collected daily
ﬁlter paper blood samples to sensitively detect and quantify par-
asites below the microscopic threshold for detection [15].
A less conventional indicator of reduced susceptibility of
malaria parasites to antimalarial drugs is the malaria transmis-
sion potential after treatment [16]. Transmission potential is
frequently reported as the prevalence or density of malarial
transmission stages (ie, gametocytes) and can be directly quan-
tiﬁed by determining the infectivity of naturally infected indi-
viduals in mosquito-feeding assays [17]. For chloroquine (CQ)
and sulfadoxine-pyrimethamine (SP), gametocyte carriage is
increased or prolonged in resistant or partially resistant para-
sites [18–20], and enhanced transmission to Anophelesmosqui-
toes has been shown for CQ-resistant parasite isolates [21].
Parasites with mutations conferring SP resistance exhibit en-
hanced transmissibility even when circulating asexual parasites
are effectively cleared by treatment [22], suggesting that, as an-
timalarial resistance develops in a population, changes in trans-
mission potential may precede changes in treatment response
[16, 22, 23]. Understanding the phenotype of enhanced parasite
transmissibility is important for predicting the spread of resis-
tant parasites.
Treatment with ACT is associated with rapid reductions in
asexual parasite densities, lower prevalence of gametocyte carriage,
and reduced but not completely abrogated posttreatment malaria
transmission [24, 25]. The association between parasite clearance
following ACT and transmissibility is unknown and regarded as
one of the key questions for successful containment of artemisinin
resistance [26, 27]. We determined the association between para-
site clearance dynamics after ACT treatment of uncomplicated
malaria in Kenyan children and posttreatment gametocyte car-
riage, malaria transmission to mosquitoes, and recurrent asexual
parasitemia during follow-up.
METHODS
Study Design, Site, and Enrollment
Between April and June 2009, a randomized, open-label trial
was conducted in Mbita Point, western Kenya, and has been
described in detail elsewhere [28]. Brieﬂy, children aged 6
months–10 years with uncomplicated malaria who were at-
tending the health facility of the International Center of Insect
Physiology and Ecology were included in the study if they had
a microscopically conﬁrmed P. falciparum monoinfection with
an asexual parasite density of 1000–200 000 parasites/μL and a
hemoglobin level of >5 g/dL. The protocol received approval
from the Kenya Medical Research Institute Ethical Review
Committee and the London School of Hygiene and Tropical
Medicine Ethics Committee (reference 5455). Written in-
formed consent was obtained from a parent or guardian of
each participating child.
Treatment, Follow-up, and Clinical and Laboratory Procedures
Eligible children were randomly allocated to receive supervised
treatment with AL (Coartem; Novartis Pharma), administered
as half a tablet (20 mg of artemether and 120 mg of lumefan-
trine) per 5 kg of body weight in a 6-dose regimen, or with DP
(Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg
piperaquine tablets), administered with targeted total doses of
6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, re-
spectively, given in 3 equally divided daily doses to the nearest
quarter tablet. New participants were enrolled into the trial on
a daily basis between 10 AM and 12 PM (noon). Follow-up sam-
pling was performed on days 1, 2, 3, 7, 14, 28, and 42 between 8
AM and 12 PM. Participants who did not attend the clinic on any
of the follow-up days were visited at home before noon. On
treatment days, sampling was done before treatment: blood
smears, dried ﬁlter paper blood spots, and 50-μL whole blood
samples were collected for microscopy, qPCR, and quantitative
nucleic acid sequence-based ampliﬁcation (QT-NASBA), re-
spectively. QT-NASBA was done for a random selection of in-
dividuals per treatment arm, as described previously [28].
MSP-1 and MSP-2 genotyping in cases of treatment failure was
performed in accordance with World Health Organization
(WHO) criteria [28, 29] but with additional time points;
samples collected on days 0, 1, 2, and 3 and at the visit before
recurrent patent parasitemia were included in each case. The
original trial report was restricted to a conventional presenta-
tion of microscopically deﬁned treatment outcomes and trans-
mission potential [28]. For the current study, a duplex qPCR
method was used to determine parasite clearance dynamics for
all patients for whom a complete set of day 0, 1, 2, and 3 ﬁlter
papers were available. qPCR was used as previously described
[15], using 6-mm punches from Whatman 3MM ﬁlter paper
(Whatman, Maidstone, United Kingdom)]. The qPCR generates
distinct ﬂuorescent signals for human (β-tubulin) and parasite
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(methionine transfer RNA gene [pgmet]) DNA targets. In the
course of validating the modiﬁed protocol used here, the assay
displayed a sensitivity comparable with that of conventional
nested PCR [30] and reliably detected parasite densities of 1
parasite/μL; lower densities were frequently detected but with a
stochastic element that is also observed for nested PCR [31].
The qPCR has a coefﬁcient of variation between 0.03% and
0.68% at densities of ≥5 parasites/μL and between 4.0% and
6.8% at lower parasite densities. The WHO international stan-
dard for P. falciparum DNA was used as positive control [15].
The following modiﬁed ampliﬁcation cycling conditions were
used in the current study: 95°C for 6 minutes and then 40
cycles of 95°C for 15 seconds and 60°C for 1 minute. qPCR
failed initially in 3 samples (ie, no β-tubulin signal was detect-
ed); repeating the samples using the same DNA material gave
interpretable results. Pfs25 QT-NASBA gametocyte carriage,
and infectiousness to mosquitoes at day 7 of follow up were de-
termined as reported elsewhere [26].
Sample Size Considerations
The current study aims to determine parasite clearance by
qPCR, a newly developed assay for which no baseline data were
available, and test for association of clearance time with treat-
ment outcome, gametocyte carriage, and malaria transmission.
Parasite clearance was evaluated in 154 individuals by qPCR.
As an indicative estimate of study power, if it is assumed a
priori that 20% of individuals might display discernibly slower
parasite clearance dynamics in the qPCR analysis and if both
treatment arms are analyzed together, this sample size could
detect, with 86% power at the 5% signiﬁcance level, a 2-fold
increase in the proportion of individuals who are infectious
to mosquitoes on day 7 after treatment, based on an average
of 30% of individuals infecting at least one mosquito [28].
Data Analysis
The main outcome of this study was parasite clearance by
qPCR. Parasite clearance dynamics were described by generat-
ing a log-linear line of best ﬁt for parasite density plotted across
the 4 time points—days 0, 1, 2, and 3. From these data, 4 pa-
rameters of interest were determined: parasite clearance time
(in hours), parasite reduction rate 48 hours after treatment,
time to 95% reduction in parasite density (in hours), and a
binary variable denoting whether parasite DNA was detectable
at day 3. The parasite reduction rate 48 hours after treatment
was arbitrarily set at 105 for isolates negative by qPCR at 48
hours. Gametocyte carriage was compared between groups as
microscopic and Pfs25 QT-NASBA gametocyte prevalence at
enrollment and day of feeding; the mean duration of gameto-
cyte carriage after treatment was estimated using a previously
published mathematical model for repeated QT-NASBA mea-
surements [32]. Continuous data were compared between
groups, using the t test or nonparametric tests. The proportion
of parasitemic or gametocytemic individuals and the propor-
tion of infectious individuals (ie, subjects who infected at least
1 mosquito) were compared between groups by the χ2 test and
logistic regression models. The proportion of infected mosqui-
toes and the oocyst burden in mosquitoes were compared
between
groups by logistic or negative binomial regression models, using
generalized estimating equations to adjust for clustering between
observations from the same individual.
RESULTS
Residual Parasitemia Detected by qPCR
As reported elsewhere, conventional microscopic assessment of
parasitological efﬁcacy found both regimens very effective at
initial parasite clearance, with only a single child in the DP arm
found to harbor detectable asexual parasitemia 3 days after
treatment [28]. Prevalence and relative density of parasitemia
determined by qPCR over the ﬁrst 72 hours following treat-
ment are plotted in Figure 1 for 154 children with a full set of
4 daily samples available. Residual parasitemia on day 3 after
initiation of treatment was observed in 33.3% (28/84) of the
children treated with AL and 30.0% (21/70) of the children
treated with DP (P = .66). The median estimated density of
these residual parasites was 0.17% (interquartile range, 0.0001–
1.54) of the enrollment parasite density and was not different
Figure 1. Plasmodium falciparum parasite prevalence and relative
density by duplex quantitative polymerase chain reaction (qPCR), by treat-
ment arm. Left y-axis, qPCR parasite prevalence (bars) for children treated
with artemether-lumefantrine (AL; n = 84) or dihydroartemisinin-pipera-
quine (DP; n = 70). Error bars indicate the upper limit of the 95% conﬁ-
dence interval. Right y-axis, median relative parasite density relative to
starting infection is plotted (line) for PCR-positive individuals treated with
AL (solid line) or DP (dashed line). All samples were collected between
10 AM and 12 PM (day 0) or between 8 AM and 12 PM (days 1, 2, and 3).
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between treatment arms (P = .26; Figure 1). qPCR positivity on
day 3 was strongly associated with the parasite reduction rate
48 hours after treatment (P < .001) and with the time to 95%
reduction in parasite density (P < .001; Table 1). We retained
the binary variable residual parasitemia by qPCR on day 3 for
exploring associations with other trial outcomes.
Children with residual parasitemia on day 3 were signiﬁ-
cantly younger (P < .001; Table 2), had a higher multiplicity of
infection at enrollment (P = .047), but did not have a
statistically signiﬁcant different enrollment asexual parasite
density (P = .91) or mean total drug dose (P≥ .34). Microscop-
ic gametocyte carriage at enrollment was signiﬁcantly more
common for children with residual parasitemia on day 3
(P = .006), whereas Pfs25 QT-NASBA–detected gametocyte
carriage was not signiﬁcantly different (P = .34). There was
limited agreement between the qPCR parasite detection and
the Pfs25 QT-NASBA gametocyte detection. On days 1, 2, and
3 after initiation of treatment, 45.0% (18/40), 53.4% (15/28),
and 50.0% (15/30), respectively, of the qPCR-positive samples
were QT-NASBA gametocyte negative. The scatter plot of
qPCR signal on day 3 and QT-NASBA gametocyte prevalence
is given in Supplementary Figure 1. The κ values for agreement
were −0.09, 0.15, and 0.25 on days 1, 2, and 3, respectively,
after initiation of treatment. The estimated parasite density
determined by qPCR was not associated with the Pfs25
QT-NASBA gametocyte prevalence on the same day (P≥ .50).
Residual Parasitemia on Day 3 and Malaria Transmission
Potential During Follow-up
Children with residual parasitemia on day 3 had a longer dura-
tion of gametocyte carriage during the 42-day follow-up period
(P = .0007; Figure 2 and Table 3). On the day of feeding experi-
ments, children with residual parasitemia on day 3 were more
likely to infect at least 1 mosquito, compared with children
whose parasites were cleared by day 3 after initiation of treat-
ment (relative risk [RR], 1.95; 95% conﬁdence interval [CI],
1.17–3.24; P = .015; Table 3). Blood from these children infect-
ed 4.0% (34/859) of the mosquitoes with 1–6 oocysts, compared
with blood donated by children who were parasite free by qPCR
Table 1. Parameters of Plasmodium falciparum Parasite
Clearance Dynamics Over the First 3 Days Following Initiation of
Treatment With Artemether-Lumefantrine (AL) or Dihydroartemisinin-
Piperaquine (DP)
Treatment, qPCR
Result on Day 3
PRR48
a , Geometric Mean
(95% CI)
PCT95,
b h ,
Median (IQR)
AL (n = 84)
Negative (n = 56) 54 984 (30 291–99 807) 5 (5–13)
Positive (n = 28) 186.0 (68.59–504.5) 39 (22–45)
DP (n = 70)
Negative (n = 49) 44 929 (21 625–93 347) 9 (5–13)
Positive (n = 21) 206.2 (70.43–603.6) 44 (30–78)
Abbreviations: CI, confidence interval; IQR, interquartile range; qPCR quanti-
tative polymerase chain reaction.
a The parasite reduction ratio 48 hours after treatment (PRR48) was estimated
from point estimates at 0 hours and 48 hours derived from qPCR data, using
the DDCT formula as previously described [16].
b The time to 95% parasite clearance (PCT95) was estimated from log-linear
line of best-fit of plotted point estimates of relative reductions in parasite
density.
Table 2. Characteristics of Individuals Whose Plasmodium falciparum Infections Were Cleared or Who Had Residual Parasitemia
Detected by Quantitative Polymerase Chain Reaction (qPCR) on Day 3 After Initiation of Treatment With Artemether-Lumefantrine (AL) or
Dihydroartemisinin-Piperaquine (DP)
Characteristic
qPCR Result on Day 3
PParasite Free (n = 105) Residual Parasitemia (n = 49)
Treated with AL 53.3 (56/105) 57.1 (28/49) .66
Total dose of lumefantrine in AL arm, mg/5 kg body weight 59.8 ± 10.1 60.1 ± 8.6 .93
Total dose of piperaquine in DP arm, mg/kg body weight 65.6 ± 7.3 67.5 ± 10.5 .34
Age, y 6 (5–8) 4 (3–6) <.0001
Characteristics on day 0 before initiation of treatment
Temperature ≥37.5°C 36.2 (38/105) 49.0 (24/49) .13
Hemoglobin level, mmol/dL, mean (95% CI) 6.8 (6.6–7.0) 6.6 (6.3–6.9) .28
Multiplicity of infection, mean (95% CI) 3.6 (3.2–3.9) 4.3 (3.7–5.0) .047
Microscopy finding
Asexual parasite density, geometric mean (95% CI) 18 560 (14 989–22 981) 13 720 (10 411–18 081) .91
Gametocyte prevalence 4.2 (4/95) 18.2 (8/44) .006
Pfs25 QT-NASBA finding
Gametocyte prevalence 71.7 (38/53) 81.5 (22/27) .34
Data are% (proportion) of participants, mean ±SD, or median (interquartile range), unless otherwise indicated.
Abbreviations: CI, confidence interval; qPCR, duplex quantitative polymerase chain reaction; QT-NASBA, quantitative nucleic acid sequence–based amplification.
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on day 3, which infected 1.6% (49/2998) of the mosquitoes with
1–4 oocysts. The proportion of infected mosquitoes (odds ratio
[OR], 2.41; 95% CI, 1.18–4.92) and the oocyst burden in mos-
quitoes (incidence rate ratio [IRR], 2.92; 95% CI, 1.61–5.31;
P < .001) were signiﬁcantly higher in experiments in children
with residual parasitemia on day 3, after adjustment for correla-
tions between observations from the same individual. These as-
sociations were not confounded by enrollment parasite density,
multiplicity of infection, treatment arm, or age.
We repeated our analyses after exclusion of children who
had microscopically detectable gametocytes at enrollment. Ga-
metocyte carriage determined by microscopy on day 7, which
was strongly associated with microscopic gametocyte carriage
at enrollment (P < .001), was no longer elevated in children
with residual parasitemia on day 3 (P = .93). Residual parasite-
mia was still signiﬁcantly associated with a longer duration of
Pfs25 NASBA gametocyte carriage (P = .021), a higher likeli-
hood of infecting at least 1 mosquito (OR, 3.71; 95% CI, 1.01–
13.66; P = .049), and a higher oocyst burden in mosquitoes
(IRR, 1.85; 95% CI, 1.02–3.35; P = .040). Because 75.0% (60/80)
of children with qPCR results harbored gametocytes as deter-
mined by QT-NASBA at enrollment and because de novo
gametocyte production was rare, we did not restrict our analy-
ses to children who were gametocyte free at enrollment accord-
ing to QT-NASBA.
Residual Parasitemia on Day 3 and Parasite Recurrence
During Follow-up
Among the 154 children for whom clearance dynamics were
measured, 25 had recurrent parasitemia detected by microsco-
py on days 28 or 42. Of these children, 84.0% (21/25) had resid-
ual parasitemia on day 3, compared with 21.7% (28/129) among
children who remained parasite free according to microscopy
during follow-up (RR, 11.25; 95% CI, 4.08–31.01; P < .001).
This association was not confounded by age, treatment arm,
enrollment parasite density, or total administered drug dose.
The multiplicity of infection at enrollment was weakly associat-
ed with recurrent parasitemia during follow-up (OR for each
additional clone 1.25; 95% CI, .96–1.61; P = .093), but the asso-
ciation between residual parasitemia on day 3 and recurrent
Table 3. Association Between Residual Parasitemia on Day 3 After Initiation of Treatment and Malaria Transmission Potential
Characteristic
qPCR Result on Day 3
PParasite Free Residual Parasitemia
Duration of gametocyte carriage, d, mean (95% CI) 6.6 (4.7–9.3) 14.5 (9.4–22.3) .0007
Microscopy finding on feeding day
Gametocyte prevalence 5.0 (5/100) 11.1 (5/45) .18
Gametocyte density, gametocytes/μL, median (IQR)a 48.0 (16.0–48.0) 64.0 (48.0–208.0) .24
Pfs25 QT-NASBA finding on feeding day
Gametocyte prevalence 30.2 (13/43) 48.2 (13/27) .13
Individuals participating in membrane feedings, no. 101 29
Infected ≥1 mosquito 24.8 (25/101) 48.3 (14/29) .015
Infected mosquitoes, no. (proportion) 1.6 (49/2998) 3.96 (34/859) .016b
Oocysts in infected mosquitoes, no., mean (range) 1.3 (1–4) 1.8 (1–6) .001b,c
Data are% (proportion) of participants, unless otherwise indicated.
Abbreviations: CI, confidence interval; IQR, interquartile range; qPCR, duplex quantitative polymerase chain reaction; QT-NASBA, quantitative nucleic acid
sequence–based amplification.
a Data are for gametocyte carriers only.
b Adjusted for correlations between observations from the same individual.
c Determined using a negative binomial regression model that incorporated both prevalence and intensity of infection among mosquitoes.
Figure 2. Plasmodium falciparum gametocyte prevalence by quantita-
tive nucleic acid sequence–based ampliﬁcation for children whose infec-
tion cleared or who had residual parasitemia detected by duplex
quantitative polymerase chain reaction on day 3 after treatment with arte-
mether-lumefantrine or dihydroartemisinin-piperaquine. Error bars indicate
the upper limit of the 95% conﬁdence interval.
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parasitemia during follow-up remained statistically signiﬁcant
after adjustment for multiplicity of infection (P < .001). For all
25 children, we performed merozoite antigen genotyping anal-
ysis on days 0, 1, 2, the scheduled follow-up day preceding
failure, and the day of failure. PCR was successful for 24 of 25
samples from day 0, 23 of 24 from day 1, 18 of 25 from day 2,
17 of 24 from the day before failure, and 24 of 25 from day of
failure. As a result, 96.0% (24/25) of the individuals had ≥2 ob-
servations from the parasite population within 48 hours of
treatment, and 64.0% (16/25) had 2 observations from the par-
asite population at or shortly before microscopy-detected para-
sitological treatment failure. Reworking WHO criteria to suit
this approach [29], recrudescent infections were deﬁned as the
presence of ≥1 allele on the day of failure or the day preceding
failure that were also present on ≥1 of days 0–2. By using these
criteria, 19 infections were now classiﬁed as recrudescent and
6 as new infections. Residual parasitemia on day 3 remained
signiﬁcantly associated with both recrudescent infections
(RR, 11.43; 95% CI, 3.49–37.40; P < .001) and new infections
(RR, 10.71; 95% CI, 1.29–89.27; P = .006).
DISCUSSION
In this study, we provide the ﬁrst evidence from Africa that
low-density residual parasitemia after treatment with ACT is
common and has consequences for onward malaria transmis-
sion to mosquitoes. Children with residual parasitemia detected
by qPCR on day 3 after initiation of treatment had a longer du-
ration of gametocyte carriage, were more likely to infect mos-
quitoes, and infected a higher proportion of mosquitoes. In
addition, they were >10-fold more likely to have recurrent mi-
croscopic asexual parasite carriage during follow-up.
Despite excellent parasite clearance rates by microscopy [28],
we observed that residual parasitemia detected by PCR persist-
ed in approximately one third of ACT-treated children until
day 3 after initiation of treatment. Submicroscopic parasite car-
riage persisting after ACT has recently been described in Sudan
and Ghana [33, 34], but because PCR is not routinely used to
monitor parasite clearance dynamics, it is currently unknown
how often parasites remain PCR detectable after successful
ACT treatment. Our study is the ﬁrst to directly relate parasite
clearance dynamics after ACT to malaria transmissibility. We
show that children who had residual parasitemia on day 3 after
treatment initiation had a longer duration of gametocyte car-
riage, were more likely to be infectious to mosquitoes, and in-
fected more mosquitoes with a higher oocyst burden. These
associations remained apparent if children with microscopical-
ly detectable gametocytes at enrollment were excluded from the
analyses.
The association between slow parasite clearance and gameto-
cyte carriage is at least partly the result of ongoing gametocyte
production by persisting asexual parasites [19]. Because ACT
rapidly clears the pool of asexual parasites from which gameto-
cytes are derived [8] and because the artemisinin-component
of ACT is given over 3 days, during which it efﬁciently clears
developing gametocytes [8, 35], it is striking that parasite-
clearance dynamics shortly after initiation of ACT determine
malaria transmission potential 1 week later. Our results conﬁrm
previous suggestions that increased gametocyte production is a
valuable marker of a slow parasite-clearance phenotype after
ACT [27, 36, 37] and are in line with ﬁndings from the Thailand–
Myanmar border, where slow microscopic parasite clearance was
associated with a longer duration of microscopic gametocyte
carriage following meﬂoquine-artesunate treatment [4]. We
conﬁrm this trend in Africa and add 2 relevant lines of evi-
dence: we show that this association is also apparent if residual
parasitemia after treatment and gametocytes are present only at
submicroscopic levels, and we provide direct evidence that this
longer duration of gametocyte carriage results in higher infec-
tivity to mosquitoes.
Similar to previous studies, we found that gametocyte carriage
at enrollment may be an indicator of subsequent treatment re-
sponses [3, 4, 38]. One may hypothesize that this indicates that
slow clearing infections are have an intrinsic higher commit-
ment to gametocyte production [39] or that slow clearing infec-
tions have been present for a longer period than fast clearing
infections and therefore have a higher likelihood of gametocyte
development during the course of infection [40]. It was recently
suggested that long-term chronic infections in equilibrium may
elicit weak immune responses and thus leave drug clearance
unassisted [34], which may result in slower parasite clearance
and longer gametocyte production. Whatever the reason,
careful monitoring of transmission potential after ACT is justi-
ﬁed by earlier demonstrations that high gametocyte production
and infectivity were linked with the development of resistance
to CQ and SP [18, 19, 21].
In our setting, we observed a strong association between resid-
ual submicroscopic parasitemia and PCR-unadjusted treatment
failure during follow-up. This association was independent of
starting parasite density, treatment arm, multiplicity of infec-
tion, and age and was not explained by differences in the ad-
ministered dose of AL or DP. Using standard methods, we
previously determined that the vast majority of recurrent infec-
tions on day 28 and day 42 were new infections [28]. It was
therefore surprising that residual parasitemia on day 3 was
strongly associated with recurrent infections. We see 3 possible
explanations for the association between early residual parasite-
mia and later recurrent infections that appear to be mostly
“new” infections. First, higher multiplicity of infection, a char-
acteristic of slow-clearing infections in this setting, may be as-
sociated with a higher malaria exposure [41] that may be stable
over time [42] and may thereby predict a higher risk of new
malaria infections during follow-up [43]. Second, immunity is
an important factor in determining parasite-clearance time [10,
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14], and slow parasite clearance may be indicative of a less efﬁ-
cient immune response in clearing parasites that may also be
associated with a higher chance of new infections becoming de-
tectable by microscopy. Third, we may have misclassiﬁed recru-
descent infections as new infections.
We have provided evidence that the third explanation is
plausible for a proportion of the infections by extending our
parasite genotyping to multiple days. The risk of overestimating
the number of recrudescent infections because some new infec-
tions may have the same genetic proﬁle as original infections is
reasonably well appreciated [44, 45]; the risk of underestimating
the number of recrudescent infections as a consequence of in-
complete detection of all parasite clones that are present at en-
rollment and failure has received less attention [46, 47]. Clones
may go undetected if genotyping is done on single days as a
consequence of sequestration of parasites, differences in clonal
densities and a stochastic element in PCR detection [31, 48].
When we analyzed sample series from the ﬁrst 3 days after en-
rollment and the day of failure combined with the day preced-
ing failure, we observed that parasites were often detectable on
all of the examined days. Based on MSP-1 and MSP-2 typing in
these extended sample sets, 15 infections that were initially
classiﬁed as new infections [28] were now classiﬁed as recrudes-
cent infections. This is in line with a study that used a similar
approach in Tanzania, where genotypes that were subsequently
found to be recrudescent were undetectable at enrollment but
detected as late as day 3 after initiation of treatment [49]. Our
data illustrate the difﬁculty of distinguishing between recrudes-
cent and new infections in areas with complex infections and
suggest that the original genotyping approach may have under-
estimated the true number of recrudescent infections [47].
In summary, we demonstrated that 24-hour DNA sampling
followed by qPCR analysis identiﬁes submicroscopic, slow-
clearing P. falciparum in approximately one third of Kenyan
children treated with ACT. Children harboring such parasites
were signiﬁcantly more likely to be infectious to mosquitoes
and are more likely to experience recurrent asexual parasitemia
on day 28 or day 42.
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